U.S. markets open in 7 minutes

Qilian International Holding Group Limited (QLI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.02+0.01 (+0.17%)
At close: 4:00PM EST

5.99 -0.03 (-0.50%)
Pre-Market: 9:22AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close6.01
Open6.10
Bid0.00 x 800
Ask6.50 x 900
Day's Range5.86 - 6.18
52 Week Range5.69 - 22.00
Volume153,372
Avg. Volume1,347,853
Market Cap215.215M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
41% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Qilian International Holding Group Limited CEO Receives Outstanding Entrepreneur Award
      GlobeNewswire

      Qilian International Holding Group Limited CEO Receives Outstanding Entrepreneur Award

      Jiuquan, China, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that its Chairman and Chief Executive Officer, Mr. Zhanchang Xin, received the Outstanding Entrepreneur Award from the Economic and Technological Development Zone of Jiuquan City in February 2021. The Outstanding Entrepreneur Award is presented to chief executive officers of businesses in a wide range of industries and sectors with leadership skills, innovation, and entrepreneurial vision. Mr. Xin commented: “I am honored to receive the Outstanding Entrepreneur Award and I am proud of all the work our team has done over the years to make it happen. The award underscores that the Company, its products and its brand have been widely recognized by our customers. Maintaining our market position and improving our branding is critical to our development. We see the award as a further validation of our leading position in the industry and a positive representation of our customers’ overall enthusiasm for our products, which will drive our business growth. This achievement also highlights the Company’s commitment and passion to produce suitable products to benefit customers and create long-term value to our investors.” About Qilian International Holding Group Limited Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company’s products are sold in more than 20 provinces in China. For more information, visit the company’s website at http://ir.qlsyy.net/. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC. For more information, please contact: Ascent Investors Relations LLCTina Xiao PresidentPhone: 917-609-0333Email: tina.xiao@ascent-ir.com

    • Qilian International Holding Group Limited Reports Fiscal Year 2020 Financial Results
      GlobeNewswire

      Qilian International Holding Group Limited Reports Fiscal Year 2020 Financial Results

      Jiuquan, China, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced its financial results for the fiscal year ended September 30, 2020. Mr. Zhanchang Xin, Chairman and CEO of the Company, commented: “We are pleased with our fiscal year 2020 financial results as we recorded revenue of US$50 million, which was in line with our expectations. The past year was a difficult year for our Company due to the challenges of COVID-19 pandemic, but we continued to grow our business, execute on our strategic priorities, and deliver value to our partners, customers and shareholders. It demonstrates that we have the innovation, diversification, stability, resilience and national scale to perform well in this challenging environment. While we believe the current market conditions will persist in the short-term, we expect to see demand growth in the long run.” Mr. Xin continued: “We are proud of the Company with over 50 years of history and in the pharmaceutical and chemical industry in China. Our successful initial public offering in January 2021 was yet another milestone for the Company and we are pleased to be in a position to continue pursuing the significant growth opportunities that lie ahead. We look forward to building on our momentum in 2021 and beyond, and we are confident that we are well-positioned to continue driving significant long-term value for our shareholders.” Fiscal Year 2020 Financial Highlights For the Year Ended September 30,($ millions, except per share data) 2020 2019 % ChangeNet revenue 50.0 46.1 9% Oxytetracycline & Licorice products and TCMD 32.6 30.1 8% Heparin products and Sausage casing 16.7 15.4 9% Fertilizer 0.7 0.5 28%Gross profit 7.5 9.7 -22%Gross margin 15.1% 21.0% -5.9 pp*Income from operations 4.8 6.2 -22%Net income attributable to Qilian International Holding Group Limited 5.1 5.3 -5%Earnings per ordinary share 0.17 0.18 -6%EBITDA 7.2 8.4 -14% *Notes: pp represents percentage points Net revenue was $50.0 million, an increase of 9% from $46.1 million in fiscal year 2019.Gross profit was $7.5 million, a decrease of 22% from $9.7 million in fiscal year 2019.Gross margin was 15.1% compared with 21.0% in fiscal year 2019.Net income attributable to Qilian International Holding Group Limited was $5.1 million, a decrease of 5% from $5.3 million in fiscal year 2019.Basic and diluted earnings per ordinary share was $0.17, compared with $0.18 in fiscal year 2019.EBITDA was $7.2 million, a decrease of 14% from $8.4 million in fiscal year 2019. Fiscal Year 2020 Financial Results Net Revenue Net revenue increased by $3.9 million, or 9% to $50.0 million in fiscal year 2020, from $46.1 million in fiscal year 2019, which was primarily attributable to a $2.5 million increase in sales from oxytetracycline products and licorice products, and a $1.3 million increase in sales from heparin products and sausage casings. For the Year Ended September 30, 2020 2019 ($ millions) Revenue Cost of revenue Gross margin Revenue Cost of revenue Gross marginOxytetracycline & Licorice products and TCMD 32.6 25.0 23.3% 30.1 22.3 26.0%Heparin products and Sausage casing 16.7 17.2 -2.7% 15.4 13.9 9.7%Fertilizer 0.7 0.3 56.6% 0.5 0.2 66.0%Total 50.0 42.5 15.1% 46.1 36.4 21.0% Sales for oxytetracycline products, licorice products and TCMD increased by $2.5 million, or 8% to $32.6 million in fiscal year 2020, from $30.1 million in fiscal year 2019. The increase in sales in this segment is due to the following reasons: (1) we conducted our scheduled facility maintenance from July 2019 to September 2019, which resulted in reduced oxytetracycline production by approximately 386 tons (a 16% decrease compared to that of fiscal year 2020). Although the outbreak of COVID-19 in early 2020 had negative impact of the manufacturing, we resumed production on February 27, 2020. Due to the production suspension in 2019, the quantity sold in 2019 was 16% less than the sales quantity in 2020, which contributed to $3.9 million of increase in sales in 2020. (2) Sales price per unit decreased by 5%, which is considered as normal in the course of business. The sales decreased by $0.6 million due to the price change. (3) during the COVID-19 outbreak in China, we switched part of our production lines to manufacture disinfection products in light of a shortage of such products, which contributed $148,000 in sales for the year ended September 30, 2020; (4) The sales increase in this segment was offset to a certain degree by a decrease in sales of licorice products. The COVID-19 outbreak in China during January to March had a significant impact on the sales of our licorice products. The sales volume of our licorice products decreased by 16% due to the logistics restraint and delays caused by China’s national lockdown during the COVID-19 outbreak. However, the market price of our licorice products had increased by 9% compared to same period in the last year due to the market’s high demand. Overall, the sales from our licorice products decreased by $0.3 million. (5) Due to the exchange rates, the sales for the year ended September 30, 2020 denominated in USD reduced by $0.6 million compared to that for the year ended September 30, 2019. Sales from heparin products increased by $1.3 million, or 9%, to $16.7 million in fiscal year 2020, from $15.4 million in fiscal year 2019. The increase of our sales of heparin products was mainly driven by the demand from our two long-term pharmaceutical customers. However, our sales of sausage casing were decreased by $2.3 million due to the combined effect of COVID-19 outbreak and African Swine fever in China. Sales from fertilizer increased by $0.2 million, or 28%, to $0.7 million in fiscal year 2020, from $0.5 million in fiscal year 2019. The increase in our sales of fertilizer products was due to our newly developed customers and regulatory policy of decreasing use of non-organic fertilizer and pesticide. Our fertilizer products are mainly organic and more environmental friendly. Cost of Revenue and Gross Profit Cost of revenue increased by $6.1 million, or 17%, to $42.5 million in fiscal year 2020, from $36.4 million in fiscal year 2019. Gross profit decreased by $2.2 million, or 22%, to $7.5 million in fiscal year 2020, from $9.7 million in fiscal year 2019. Gross margin decreased by 5.9 percentage points to 15.1% in fiscal year 2020, compared with 21.0% in fiscal year 2019. Selling, General and Administrative Expenses Selling, general and administrative expenses decreased by $0.8 million, or 22%, to $2.7 million in fiscal year 2020, from $3.5 million in fiscal year 2019. The decrease was mainly attributable to the decrease of approximately $0.7 million in consulting and professional fees related to our effort to go public which were not eligible to be capitalized in accordance with the U.S. GAAP. As 2019 was the first year we prepared the public listing and filing, the majority filing cost were incurred in 2019. Interest Expenses Interest expenses are primarily generated from bank borrowings including bank loans and banknotes payable. Interest expenses were $243,000 in fiscal year 2020, compared with $224,000 in fiscal year 2019. Other Income Other income was $1.2 million in fiscal year 2020 as compared to $1.0 million in fiscal year 2019, which was primarily consists of government grants and other non-operating incomes. Income taxes Provision Provision for income taxes decreased by $0.2 million, or 16%, to $0.8 million in fiscal year 2020, from $1.0 million in fiscal year 2019, as a result of the decreased income before income tax provision. Income before income tax provision was $5.8 million in fiscal year 2020, compared to $6.9 million in fiscal year 2019. Net Income Attributable to the Company’s Shareholders Net income attributable to the Company’s shareholders decreased by $0.3 million, or 5%, to $5.0 million in fiscal year 2020, from $5.3 million in fiscal year 2019. Basic and diluted earnings per ordinary share were $0.17 in fiscal year 2020, compared with basic and diluted earnings per ordinary share of $0.18 in fiscal year 2019. EBITDA EBITDA decreased by $1.2 million, or 14%, to $7.2 million in fiscal year 2020, from $8.4 million in fiscal year 2019. Balance Sheet As of September 30, 2020, the Company had cash of $11.9 million, compared with $4.6 million as of September 30, 2019. Cash Flow Net cash provided by operating activities was $5.1 million in fiscal year 2020, compared with net cash used in operating activities of $0.6 million in fiscal year 2019. Net cash used in investing activities was $0.4 million in fiscal year 2020, compared with $0.7 million in fiscal year 2019. Net cash used provided by financing activities was $2.1 million in fiscal year 2020, compared with $0.4 million in fiscal year 2019. Non-GAAP Financial Measures The Company’s management uses certain financial measures to evaluate its operating performance which is calculated and presented on the basis of methodologies other than in accordance with GAAP (“Non-GAAP”). These measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP, and the Company’s calculations thereof may not be comparable to similarly entitled measures reported by other companies. The Company believes that EBITDA is a useful performance measure and can be used to facilitate a comparison of its operating performance on a consistent basis from period to period and to provide for a more complete understanding of factors and trends affecting its business than GAAP measures alone can provide. The Company’s management believes that EBITDA is less susceptible to variances in actual performance resulting from depreciation, amortization and other non-cash charges and more reflective of other factors that affect its operating performance. The Company’s management believes that the use of these Non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with the companies in the same industry, many of which present similar Non-GAAP financial measures to investors. The Company presents EBITDA in order to provide supplemental information that Management considers relevant for the readers of its consolidated financial statements included elsewhere in this annual report, and such information is not meant to replace or supersede U.S. GAAP measures. The Company’s management defines EBITDA as net income (loss) before interest expense, income taxes, and depreciation and amortization. EBITDA is not defined under U.S. GAAP and is subject to important limitations as analytical tools, you should not consider them in isolation or as substitutes for analysis of our Company results as reported under U.S. GAAP. For the Years ended September 30, 2020 2019Net income $4,940,441 $5,908,479Interest expense 242,877 223,657Income tax provision 864,908 1,033,440Depreciation & Amortization 1,105,588 1,188,173EBITDA $7,153,814 $8,353,749 Recent Developments On February 8, 2021, the Company announced that it will complete the first phase expansion of its new organic fertilizer production facility in Jiuquan City, Gansu Province and put it into production by March 2021. The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion. On January 19, 2021, the Company announced that the underwriters of its initial public offering had exercised in full their option to purchase an additional 750,000 ordinary shares at a public offering price of $5.00 per share to cover overallotments. Gross proceeds of the Company's initial public offering, including the exercise of the overallotment, totaled $28.75 million, before deducting underwriting discounts and other related expenses. On January 14, 2021, the Company announced the closing of its initial public offering of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The Company received aggregate gross proceeds of US$25 million, before deducting underwriting discounts and other related expenses. On January 11, 2021, the Company announced the pricing of its initial public offering of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Market and began trading on January 12, 2021 under the ticker symbol “QLI”. About Qilian International Holding Group Limited Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company’s products are sold in more than 20 provinces in China. For more information, visit the company’s website at http://ir.qlsyy.net/. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC. For more information, please contact: Ascent Investors Relations LLCTina Xiao PresidentPhone: 917-609-0333Email: tina.xiao@ascent-ir.com Qilian International Holding Group Limited and SubsidiariesConsolidated Balance Sheets As of September 30 September 30 2020 2019 ASSETS CURRENT ASSETS: Cash $ 11,867,130 $ 4,594,440 Accounts receivable, net 1,118,476 603,760 Bank acceptance notes receivable 11,498,075 5,476,707 Inventories, net 11,994,471 12,522,884 Advances to suppliers, net 491,827 958,005 Other current assets 547,443 813,932 TOTAL CURRENT ASSETS 37,517,422 24,969,728 Property and equipment, net 7,419,028 7,665,322 Intangible assets, net 1,881,722 1,834,130 Long term investment 540,517 539,680 Operating lease right of use assets 243,874 - Deferred tax assets 361,250 259,384 Security deposit 179,325 - TOTAL ASSETS $ 48,143,138 $ 35,268,244 CURRENT LIABILITIES: Bank loans $ 7,349,375 $ 4,903,128 Accounts payable 4,377,712 3,570,148 Advance from customers 3,511,198 1,911,748 Advance from customers - related parties 33,152 2,171 Deferred government grants-current 384,802 391,142 Taxes payable 1,383,182 347,930 Operating lease liabilities, current 82,468 - Accrued expenses and other payables 1,301,882 531,713 TOTAL CURRENT LIABILITIES 18,423,771 11,657,980 LONG TERM LIABILITIES Operating lease liabilities, noncurrent 155,723 - Deferred government grants - noncurrent 722,137 972,338 TOTAL LIABILITIES 19,301,631 12,630,318 Commitments and contingencies EQUITY: Ordinary Shares, $0.00166667 par value, 100,000,000 shares authorized , 30,000,000 Ordinary Shares issued and outstanding as of March 31, 2020 and September 30, 2019 , respectively 50,000 50,000 Additional paid-in capital 12,252,077 12,252,077 Statutory Reserve 2,200,786 1,773,817 Retained earnings 12,197,372 7,560,631 Accumulated other comprehensive loss (602,001) (1,743,175) Total shareholders’ equity attributable to Qilian International 26,098,234 19,893,350 Noncontrolling interests 2,743,273 2,744,576 TOTAL EQUITY 28,841,507 22,637,926 TOTAL LIABILITIES AND EQUITY$ 48,143,138 35,268,244 Qilian International Holding Group Limited and SubsidiariesConsolidated Statements of Income and Comprehensive Income For the year ended September 30 2020 2019 2018 NET REVENUE$ 50,033,200 $ 46,096,684 $ 50,369,013 COST OF REVENUE 42,494,047 36,416,772 42,236,773 GROSS PROFIT 7,539,153 9,679,912 8,132,240 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 2,728,009 3,501,374 2,160,873 INCOME FROM OPERATIONS 4,811,144 6,178,538 5,971,367 Other Income (Expenses) Interest expense (242,877) (223,657) (216,187) Other income 1,237,082 987,038 390,792 Total Other income (expense) 994,205 763,381 174,605 INCOME BEFORE INCOME TAX PROVISION 5,805,349 6,941,919 6,145,972 PROVISION FOR INCOME TAXES 864,908 1,033,440 943,363 NET INCOME 4,940,441 5,908,479 5,202,609 Less: net income attributable to non-controlling interest (123,269) 576,161 33,102 NET INCOME ATTRIBUTABLE TO QILIAN INTERNATIONAL HOLDING GROUP LIMITED$ 5,063,710 $ 5,332,318 $ 5,169,507 OTHER COMPREHENSIVE INCOME Foreign currency translation adjustment 1,263,140 (858,337) (652,232) COMPREHENSIVE INCOME 6,203,581 5,050,142 4,550,377 Less: comprehensive income attributable to non - controlling interests (1,303) 478,722 (35,398) COMPREHENSIVE INCOME ATTRIBUTABLE TO QILIAN INTERNATIONAL HOLDING GROUP LIMITED$ 6,204,884 $ 4,571,420 $ 4,585,775 Earnings per common share - basic and diluted$ 0.17 $ 0.18 $ 0.17 Weighted average shares - basic and diluted 30,000,000 30,000,000 30,000,000 Qilian International Holding Group Limited and Subsidiaries Consolidated Statements of Cash flows For the year ended September 30 2020 2019 2018 Cash flows from operating activities: Net Income$ 4,940,441 5,908,479 5,202,609 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Amortization of the Right-of-use assets 62,410 - Depreciation and amortization 1,105,588 1,188,173 1,254,098 Loss from disposal of property and equipment - - 4,389 Provision of doubtful accounts 188,095 (9,301) 8,329 Inventory reserve (290,968) 67,719 201,053 Deferred tax expense (86,495) 48,656 15,799 Investment income (57,984) (89,197) (8,303) Changes in operating assets and liabilities: Accounts receivable (660,667) 706,582 (1,072,933) Bank acceptance notes receivable (5,583,925) (2,171,300) (2,989,921) Inventories 1,402,620 (3,492,342) 2,812,032 Advances to suppliers 498,378 653,028 (156,114) Advances to suppliers - related parties, net - - 239,250 Other current assets 125,261 (29,853) (32,169) Accounts payable 613,339 (46,999) (822,019) Accounts payable - related parties - (3,042) (2,526) Advance from customers 1,461,407 (2,232,858) (267,520) Advance from customers - related parties 29,973 2,254 (11,694) Deferred revenue (314,238) (319,982) (385,118) Tax payables 988,423 (834,183) 648,173 Accrued expenses and other payables 722,284 73,969 (199,400) Operating lease liabilities (67,928) - - Net cash provided by (used in) operating activities 5,076,014 (580,197) 4,438,015 Cash flows from investing activities: Purchase of property and equipment (449,766) (616,388) (1,117,175) Purchase of intangible assets (8,798) (635) - Proceeds from (Payment made for) long term investment 82,972 (64,165) (253,596) Investment made for marketable securities - 14,559 (15,309) Net cash used in investing activities (375,592) (666,629) (1,386,080) Cash flows from financing activities: Proceeds from bank loans 7,135,009 5,089,651 (1,529,052) Repayment of bank loans (4,994,506) (3,635,465) - Repayment of bank notes payable - (581,674) (1,100,917) Capital contribution from shareholders - - 247,700 Cash dividend paid - - (733,944) Payment for deferred offering costs - (365,310) - Acquisition of non-controlling interest - (133,552) - Net cash provided by financing activities 2,140,503 373,650 (3,116,213) Effect of exchange rate change on Cash 431,765 (157,163) (181,798) Net increase (decrease) in cash and cash equivalents 7,272,690 (1,030,339) (246,076) Cash and cash equivalents at beginning of year 4,594,440 5,624,779 5,870,855 Cash and cash equivalents at end of year$ 11,867,130 4,594,440 5,624,779 Supplemental cash flow information Cash paid for interest$ 280,169 $ 210,588 $ 223,773 Cash paid for income taxes$ 275,607 $ 1,109,655 $ 658,409 Operating lease right of use assets obtained in exchange of lease liabilities$ 143,443 $ - $ - Stock divdend appropriation to shareholders$ - $ - $ 4,403,670

    • Qilian International Holding Group Limited to Triple Organic Fertilizer Production Capacity by March 2021
      GlobeNewswire

      Qilian International Holding Group Limited to Triple Organic Fertilizer Production Capacity by March 2021

      Jiuquan, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company will complete the first phase expansion of its new organic fertilizer production facility and put it into production in Jiuquan City, Gansu Province by March 2021. The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion. Currently, the Company’s organic fertilizer products are mainly sold to the China’s five northwestern provincial-level regions, namely Shaanxi, Gansu, Qinghai, Ningxia, Xinjiang and other regions including Sichuan, Shanxi, Tibet and Inner Mongolia. With a tripled production capacity, the Company has won bids for government organic fertilizer projects in Tibet, Gansu and Qinghai. After completing the first phase expansion, the Company will mainly focus on producing and selling bio-organic fertilizers under the "Moshangfa" and "Xiongguan" brands. Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, “the Chinese government pays great attention to the issues of ‘agriculture, rural areas and farmers’ and strives to maintain at least 1.8 billion mu (approximately 296.5 million acres) of arable land in China. As each mu of arable land consumes 150-200 kilograms of organic fertilizer, the organic fertilizer market in China has tremendous potential. We will seek to provide solutions for the ‘degradation, acidification, salinization’ of China's arable land. Looking forward, we expect that our organic fertilizer business become a new growth point for our Company and create long-term value to our investors.” About Qilian International Holding Group Limited Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company’s products are sold in more than 20 provinces in China. For more information, visit the company’s website at http://ir.qlsyy.net/. Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC. For more information, please contact: Ascent Investors Relations LLCTina Xiao PresidentPhone: 917-609-0333Email: tina.xiao@ascent-ir.com